Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of the FDA’s rejection of a key multiple sclerosis pill, and a late-stage
Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended
Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
